Harmony Biosciences Holdings, Inc.

NASDAQ:HRMY

Biotechnology

Healthcare
$33.11 -1.81%

-$0.61 today

Market cap
$1.94B
Beta
0.97
P/E (TTM)
13.2
EPS (TTM)
$2.52
52W Low $25.52High $40.87

Volume 0.57M

Average 0.82M

HRMY Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Harmony Biosciences Holdings, Inc.NASDAQ: HRMY

Net Debt · Q2 FY2026 · quarter ended Jun 2026

Net debt remains negative

Q2 FY2026 net debt was -$395.81M, compared with -$372.68M a year earlier.

Context

  • Net debt amounted to 28.8% of total assets at the end of Q2 FY2026, down 4.8 pp from a year earlier.
  • Net debt grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net debt keeps falling in the next quarterly balance sheet after a -6.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$395.81M-3.4% QoQ
Last fiscal yearDec 2025
-$512.92M-88.9% YoY
Year agoJun 2025
-$372.68M-6.2% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.2%——
1 year-88.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
(512.92M) USD
Year-over-year change
-88.9%

Net Debt vs competitors

How HRMY compares with its peers on the latest reported figures

  • HRMY's Jun 2026 net debt of -$395.81M is the 2nd highest of the 4 companies compared; the peer median is -$463.18M.
  • Its year-over-year change of -6.2% is the highest of 4, against a peer median of -2931.4%.
  • Net debt amounts to 28.8% of total assets for HRMY, versus a peer median of 80.6%.
HRMY Competitors Peer median
Net Debt for HRMY and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
LBRXLB Pharmaceuticals Inc Common StockMar 2026-$317.21M -2931.4%—80.6%
HRMYHarmony Biosciences Holdings, Inc.Jun 2026-$395.81M -6.2%—28.8%
CMPSCOMPASS Pathways plcMar 2026-$463.18M -103.1%—87.1%
NERVMinerva Neurosciences, Inc.Jun 2026-$24.58B -161104.7%—25.8%
APMDApnimed, Inc.—— ———
Peer median (excluding HRMY) -$463.18M-2931.4%—80.6%

Competitors are the stored peer set for HRMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents234.31M243.78M311.66M453M752.5M
Short-term Investments079.33M41.8M14.19M22.84M
Net Receivables34.84M54.74M74.14M83.03M96.79M
Inventory4.43M4.3M5.36M7.2M5.36M
Other Current Assets3.22M8.79M5.54M8.12M13.52M
Total Current Assets284.44M400.29M451.07M579.25M907.01M
Property, Plant & Equipment (Net)4.12M573K371K3.38M5.34M
Goodwill00000
Intangible Assets143.92M160.95M137.11M113.26M89.42M
Long-term Investments022.57M72.17M108.87M107.4M
Tax Assets085.94M144.16M0149.7M
Other Non-current Assets967K3.55M6.57M194.43M12.76M
Total Non-current Assets149M273.59M360.38M419.95M364.62M
Total Assets433.44M673.87M811.45M999.2M1.27B
Account Payables1M3.79M17.73M13.74M17.69M
Short-term Debt2M2M15M16.25M86.89M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities01.62M107.3M4.35M129.1M
Total Current Liabilities53.78M78.88M163.78M175.08M252.13M
Long-term Debt189.98M189.65M178.57M163.02M148.18M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities777K2.5M2.11M1.13M(3.41M)
Total Non-current Liabilities193.16M192.15M180.68M164.96M149.28M
Total Liabilities246.94M271.03M344.46M340.05M401.41M
Common Stock1K1K1K1K1K
Retained Earnings(453.6M)(272.13M)(143.28M)2.22M160.9M
Accumulated OCI0(151K)2K66K346K
Other Stockholders Equity00000
Minority Interest00000
Total Equity186.51M402.84M466.99M659.16M870.22M
Total Debt195.74M191.65M193.57M181.41M239.58M
Net Debt(38.57M)(52.14M)(118.09M)(271.6M)(512.92M)

Harmony Biosciences Holdings, Inc.

NASDAQ:HRMY

Intrinsic Alpha fair value

Locked

Current Price

$33.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.